Disease Landscape and Forecast Insights

Myelofibrosis is a hematological malignancy characterized by disrupted blood cell production and bone marrow scarring. Symptoms include severe anemia, weakness, fatigue, and splenomegaly. The JAK…

Clarivate Epidemiology’s coverage of the RSV vaccine comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany…

The launch of several novel therapies, as well as multiple label expansions of existing drugs, will fuel significant growth of the NHL therapy market in China over the next 10 years. Rituximab (…

The type 2 diabetes (T2D) therapy market will expand through 2033, supported by polypharmacy and growing use of later-line therapies offering nonglycemic benefits. However, the loss of exclusivity…

The chronic kidney disease (CKD) therapy market comprises a wide variety of antihypertensive agents and SGLT-2 inhibitors to delay the progression of kidney damage. RAAS inhibitors are the standard…

Treatment of multiple myeloma is complex. It involves a combination of proteasome inhibitors and/or immunomodulatory drugs (IMiDs) with chemotherapy. Treatment may also include cell-surface-…

The hepatocellular carcinoma therapy market is experiencing substantial growth. Angiogenesis inhibitors have played a central role in treating advanced disease, but the approval of immunotherapies…

Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course, manifestations, and treatment approach can be…

The schizophrenia therapy market is crowded and dominated by atypical and typical antipsychotics. Although the continued generic erosion of atypical antipsychotics influences psychiatrists’…

Type 2 diabetes (T2D) remains one of the biggest public health concerns in China, where the disease’s prevalence is globally the highest. Biguanides continue to dominate the market, but the use of…

We expect the ulcerative colitis (UC) therapy market to grow steadily over the next decade, primarily driven by the increasing use of non-tumor necrosis factor (TNF) biologics (e.g., Takeda’s…